Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 6/20 | 0.39 |
| ▸ | NPY1R | P25929 | 5/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.39 |
| ▸ | NPY2R | P49146 | 3/20 | 0.39 |
| ▸ | GLP1R | P43220 | 3/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607984 | 1.00 | NOD1 (0.40) | NOD1ENPEPFOLH1RXFP1NPY4R | |
| SCHEMBL30563214 | 0.94 | NOD1 (0.40) | NOD1RXFP1NPY4RNPY1RNPY5R | |
| SCHEMBL29587324 | 0.93 | ENPEP (0.42) | NOD1ENPEPNPY4RNPY1RNPY5R | |
| SCHEMBL27637835 | 0.92 | FOLH1 (0.44) | NOD1ENPEPFOLH1NPY4RNPY1R | |
| SCHEMBL27637834 | 0.92 | FOLH1 (0.44) | NOD1ENPEPFOLH1NPY4RNPY1R | |
| SCHEMBL29772973 | 0.90 | NOD1 (0.41) | NOD1FOLH1NPY4RNPY1RNPY5R | |
| SCHEMBL29678580 | 0.90 | TERT (0.42) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30173158 | 0.89 | ENPEP (0.41) | ENPEPRXFP1 | |
| SCHEMBL15268407 | 0.89 | RXFP1 (0.42) | NOD1RXFP1NPY4RNPY1RNPY5R | |
| SCHEMBL15268406 | 0.89 | RXFP1 (0.42) | NOD1RXFP1NPY4RNPY1RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5627268-A | MAKING A DESIRED PEPTIDE IN TRANSGENIC ANIMALS | DNX BIOTHERAPEUTICS (US) | 1997-05-06 | — | — | US | claimed |
| EP-4339284-B1 | RECOMBINANT PROTEINS DERIVED FROM GENUS LIMULUS, AND DNA MOLECULES ENCODING SAME | SEIKAGAKU KOGYO CO LTD (JP) | 2026-05-27 | — | — | EP | disclosed |
| EP-4745235-A2 | RECOMBINANT PROTEINS DERIVED FROM GENUS LIMULUS, AND DNA MOLECULES ENCODING SAME | Seikagaku Corporation (JP) | 2026-05-20 | — | — | EP | disclosed |
| EP-3517962-B1 | AN AGENT FOR MEASURING ENDOTOXIN | SEIKAGAKU KOGYO CO LTD (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | IPSEN BIOPHARM LIMITED (GB) | 2026-03-31 | — | — | US | disclosed |
| US-20260071227-A1 | METHOD FOR SECRETORY PRODUCTION OF PROTEINS | AJINOMOTO CO., INC. (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4667580-A1 | METHOD FOR SECRETORY PRODUCTION OF PROTEINS | AJINOMOTO CO., INC. (JP) | 2025-12-24 | — | — | EP | disclosed |
| US-12365742-B2 | Compositions and methods for t-cell receptor gene assembly | ROOTPATH GENOMICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250205335-A1 | SYNTHETIC TUMOR-INFILTRATING LYMPHOCYTES (TILS) | Hangzhou Chengyuan Biotechnology Co., Ltd. (CN) | 2025-06-26 | — | — | US | disclosed |
| WO-2025128693-A1 | AN ENGINEERED MAMMALIAN NUCLEASE FOR IMPROVED MAPPING OF 3-D GENOME ARCHITECTURE FROM NUCLEOSOME TO CHROMOSOME SCALE | THE ROCKEFELLER UNIVERSITY (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-0871749-A1 | OIL BODY PROTEINS AS CARRIERS OF HIGH VALUE PROTEINS | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 1998-10-21 | — | — | EP | disclosed |
| US-5650554-A | EXPRESSION OF RECOMBINANT POLYPEPTIDE BY A PLANT OR BATERIAL HOST CELL; GENETIC ENGINEERING | SEMBIOSYS GENETICS INC. (CA) | 1997-07-22 | — | — | US | disclosed |
| WO-1996021029-A1 | OIL BODY PROTEINS AS CARRIERS OF HIGH VALUE PROTEINS | UNIVERSITY TECHNOLOGIES INTERNATIONAL, INC. (CA) | 1996-07-11 | — | — | WO | disclosed |
| US-5252466-A | Hybrids | BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0472658-A4 | FUSION PROTEINS HAVING AN IN VIVO POST-TRANSLATIONAL MODIFICATION SITE AND METHODS OF MANUFACTURE AND PURIFICATION | BIOTECHNOLOGY RES & DEV (US) | 1992-08-26 | — | — | EP | disclosed |
| EP-0472658-A1 | FUSION PROTEINS HAVING AN IN VIVO POST-TRANSLATIONAL MODIFICATION SITE AND METHODS OF MANUFACTURE AND PURIFICATION | BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION INCORPORATED (US) | 1992-03-04 | — | — | EP | disclosed |
| EP-0446283-A4 | SYNTHETIC INTERLEUKIN-6 | UNIV NORTH CAROLINA (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0446283-A1 | SYNTHETIC INTERLEUKIN-6 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1991-09-18 | — | — | EP | disclosed |
| WO-1990014431-A1 | FUSION PROTEINS HAVING AN IN VIVO POST-TRANSLATIONAL MODIFICATION SITE AND METHODS OF MANUFACTURE AND PURIFICATION | BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION (US) | 1990-11-29 | — | — | WO | disclosed |
| WO-1990006370-A1 | SYNTHETIC INTERLEUKIN-6 | THE TRUSTEES OF THE UNIVERSITY OF NORTH CAROLINA (US) | 1990-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071227-A1 | METHOD FOR SECRETORY PRODUCTION OF PROTEINS | MDH1, MDH2, MLYCD | NOD1 3426/4885ENPEP 1010/4885FOLH1 540/4885 |
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | PDXK, VIP, F13B | NOD1 699/4885ENPEP 324/4885FOLH1 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.